Roche RHHBY announced that the phase III CELESTIMO study, evaluating Lunsumio (mosunetuzumab) in combination with Revlimid ...

Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and ...

Genentech posts a late-stage trial win for a combination regimen containing its bispecific antibody Lunsumio in follicular ...

Roche announced that the phase III CELESTIMO study evaluating Lunsumio (mosunetuzumab) in combination with lenalidomide versus MabThera/Rituxan (rituximab) plus lenalidomide in people with relapsed or ...

Roche’s T-cell engager portfolio has notched another milestone, as a phase 3 trial of the company’s Lunsumio met its primary ...

The Lunsumio-based combination significantly improved progression-free survival, supporting plans to seek full approval and ...

Genentech, affiliated to Swiss drug major Roche Holding AG ( RHHBY ,RO.SW,ROG.SW), on Thursday announced that its Lunsumio-based regimen significantly improved progression-free survival in Follicular ...

Roche Holdings AG ( RHHBY ), a biopharmaceutical company, on Thursday announced that the Phase 3 CELESTIMO trial for Lunsumio plus lenalidomide had met its primary endpoint in a comparative study for ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the Phase III CELESTIMO study evaluating Lunsumio® (mosunetuzumab-axgb) in combination with lenalidomide ...